Griffiths, Jason I.
Chen, Jinfeng http://orcid.org/0000-0002-5628-6322
Cosgrove, Patrick A. http://orcid.org/0000-0001-7784-7785
O’Dea, Anne
Sharma, Priyanka
Ma, Cynthia http://orcid.org/0000-0002-8156-7492
Trivedi, Meghna
Kalinsky, Kevin
Wisinski, Kari B.
O’Regan, Ruth
Makhoul, Issam
Spring, Laura M.
Bardia, Aditya http://orcid.org/0000-0003-4885-1157
Adler, Frederick R.
Cohen, Adam L.
Chang, Jeffrey T. http://orcid.org/0000-0002-4578-5636
Khan, Qamar J. http://orcid.org/0000-0002-6287-020X
Bild, Andrea H. http://orcid.org/0000-0002-4727-5533
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA209978, P30CA042014, RP170668, U54CA209978, U54CA209978, U54CA209978, U54CA209978, U54CA209978, U54CA209978, P30CA042014, RP170668)
Article History
Received: 3 November 2020
Accepted: 23 April 2021
First Online: 3 June 2021
Competing interests
: R.O.R. participates on the advisory board for Cyclacel, PUMA, Biotheranostics, Lilly, Pfizer, Genentech and Novartis; and declares research funding from Pfizer, Novartis, Seattle Genetics and PUMA. P.S. declares research funding from Novartis, Merck and Bristol Myers Squibb; and consulting for Seattle Genetics, Merck, Novartis, Astra Zeneca, Immunomedics and Exact Biosciences. L.M.S. participates on the advisory board for Novartis, Lumicell, Puma Biotechnology and Avrobio. C.M. declares research funding from Pfizer and Puma; and consulting for Eisai, Athenex, OncoSignal, Agendia, Biovica, Astra Zeneca and Seattle Genetics. K.B.W. declares research funding and clinical trial involvement with Novartis, Eli Lilly, Astra Zeneca, Sanofi and Pfizer. He participated on an advisory board for Eisai, Pfizer and Astra Zeneca. K.K. is a medical advisor to Immunomedics, Pfizer, Novartis, Eisai, Eli Lilly, Amgen, Merck, Seattle Genetics and Astra Zeneca; receives institutional support from Immunomedics, Novartis, Incyte, Genentech/Roche, Eli Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, Zentalis Pharmaceuticals and CytomX Therapeutics; and his spouse is employed by Grail and previously by Array Biopharma and Pfizer. A.O.D. consults for Pfizer, PUMA Biotechnology, Astra Zeneca and Daiichi Sankyo. Q.J.K. declares research funding from Novartis. All other authors have no conflicts of interest to disclose.